Preclinical Activity of SAR408701: A Novel Anti-CEACAM5–maytansinoid Antibody–drug Conjugate for the Treatment of CEACAM5-positive Epithelial TumorsStéphanie Decary, Véronique Blanc|Clinical Cancer Research|2020Cited by 79
Abstract LB135: Simultaneous costimulatory T-cell engagement and checkpoint inhibition by PRS-344/S095012, a PD-L1/4-1BB bispecific compound for tumor localized activation of the immune systemAizea Morales‐Kastresana, Shane A. Olwill, Janet K. Peper-Gabriel et al.|Cancer Research|2021Cited by 1